Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Iboga root bark contains ibogaine (1.93% w/w) as its primary alkaloid, which disrupts addiction pathways through non-competitive inhibition of serotonin and dopamine reuptake while modulating NMDA, opioid, and nicotinic receptors. This multitarget mechanism induces GDNF/BDNF neurotrophic signaling that promotes neuroplasticity and reduces drug-seeking behavior in preclinical models.
Reported Benefits (Provisional)
Origin & History
Iboga Root (Tabernanthe iboga) is derived from a rainforest shrub native to Central West Africa, primarily Gabon, Cameroon, and the Republic of Congo. Revered for its psychoactive properties, this root is a cornerstone of traditional Bwiti spiritual practices and is now studied for its therapeutic potential.
Research Narrative (Provisional)
Extensive scientific studies, including clinical trials and pharmacological research, investigate Ibogaine's efficacy in addiction therapy, particularly for opioid and stimulant dependence. Research published in NCBI and ScienceDirect explores its neuroplastic effects, mechanisms in trauma processing, and pharmacokinetic profile, alongside safety considerations.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Indole Alkaloids: Primarily Ibogaine, Noribogaine, and Tabernanthine. - Neuroactive Compounds: Modulate dopaminergic, serotonergic, and opioid receptor systems. - Neurotrophic Factors: Promotes Brain-Derived Neurotrophic Factor (BDNF) expression. - Synaptic Modulators: Supports synaptic reorganization and neuroplasticity.
Reported Mechanism (Provisional)
Ibogaine non-competitively inhibits serotonin (SERT) and dopamine (DAT) reuptake transporters while stabilizing their inward-facing conformation. It acts as an NMDA receptor antagonist, binds to sigma-1/2 receptors, modulates opioid and nicotinic receptors, and demonstrates 5-HT2A agonism. This multitarget activity triggers GDNF/BDNF neurotrophic factor release, promoting dendritic arbor complexity and neural recalibration in addiction circuits.
Clinical Narrative (Provisional)
Current evidence is primarily limited to preclinical rodent studies demonstrating ibogaine's ability to reduce self-administration of opiates, amphetamines, alcohol, and nicotine. Extensive pharmacological research published in NCBI and ScienceDirect investigates ibogaine's mechanisms and safety profile, but specific human clinical trial data with quantified success rates or abstinence durations are not available in current literature. Research focuses on understanding neuroplastic effects and pharmacokinetic properties rather than controlled efficacy outcomes. Evidence strength remains at the preclinical level despite widespread interest in addiction therapy applications.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.